|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
101,390,000 |
Market
Cap: |
1.92(B) |
Last
Volume: |
668,805 |
Avg
Vol: |
662,544 |
52
Week Range: |
$12.32 - $20.04 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Innoviva is a company with a portfolio of royalties and other healthcare assets. Co.'s royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA®. Co. is entitled to royalty payments made by GSK under its agreements that assigned to Theravance Respiratory Company, LLC (TRC), including TRELEGY® ELLIPTA® and any other product or combination of products that may be discovered or developed in the future under the Long-Acting Beta2 Agonist Collaboration Agreement and the Strategic Alliance Agreement with GSK, which have been assigned to TRC other than RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
664,000 |
Total Buy Value |
$0 |
$0 |
$0 |
$8,468,005 |
Total People Bought |
0 |
0 |
0 |
2 |
Total Buy Transactions |
0 |
0 |
0 |
12 |
Total Shares Sold |
0 |
0 |
10,994 |
10,994 |
Total Sell Value |
$0 |
$0 |
$153,810 |
$153,810 |
Total People Sold |
0 |
0 |
1 |
1 |
Total Sell Transactions |
0 |
0 |
1 |
1 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Brinkley David L |
Head of Business Dev. |
|
2009-12-16 |
4 |
S |
$13.01 |
$25,448 |
D/D |
(1,956) |
11,547 |
|
- |
|
Mammen Mathai |
SVP, Research & Early Clin Dev |
|
2009-11-20 |
4 |
D |
$14.04 |
$15,444 |
D/D |
(1,100) |
101,644 |
|
- |
|
Winningham Rick E |
Chief Executive Officer |
|
2009-11-20 |
4 |
D |
$14.04 |
$33,191 |
D/D |
(2,364) |
114,040 |
|
- |
|
Shafer Bradford J |
Sr VP, Gen. Counsel, Secretary |
|
2009-11-20 |
4 |
D |
$14.04 |
$13,633 |
D/D |
(971) |
226,827 |
|
- |
|
Brinkley David L |
Head of Business Dev. |
|
2009-11-20 |
4 |
D |
$14.04 |
$9,884 |
D/D |
(704) |
13,503 |
|
- |
|
Blum Leonard M |
Sr VP, Chief Comm. Officer |
|
2009-11-20 |
4 |
D |
$14.04 |
$15,641 |
D/D |
(1,114) |
122,251 |
|
- |
|
Aguiar Michael W |
Sr VP, Chief Financial Officer |
|
2009-11-20 |
4 |
D |
$14.04 |
$19,403 |
D/D |
(1,382) |
90,482 |
|
- |
|
Brinkley David L |
Head of Business Dev. |
|
2009-09-15 |
4 |
S |
$17.86 |
$160,708 |
D/D |
(9,000) |
14,207 |
|
- |
|
Brinkley David L |
Head of Business Dev. |
|
2009-09-15 |
4 |
OE |
$8.53 |
$76,725 |
D/D |
9,000 |
23,207 |
|
- |
|
Aguiar Michael W |
Sr VP, Chief Financial Officer |
|
2009-09-13 |
4 |
D |
$18.20 |
$81,318 |
D/D |
(4,468) |
91,864 |
|
- |
|
Mammen Mathai |
SVP, Research & Early Clin Dev |
|
2009-08-20 |
4 |
D |
$15.65 |
$16,761 |
D/D |
(1,071) |
102,744 |
|
- |
|
Levine Arnold J |
Director |
|
2009-06-15 |
5 |
GD |
$0.00 |
$0 |
D/D |
63,967 |
12,000 |
|
- |
|
Brinkley David L |
Head of Business Dev.Officer |
|
2009-06-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
14,413 |
|
- |
|
Aguiar Michael W |
Sr VP, Chief Financial Officer |
|
2009-05-20 |
4 |
D |
$14.06 |
$18,939 |
D/D |
(1,347) |
97,679 |
|
- |
|
Winningham Rick E |
Chief Executive Officer |
|
2009-05-20 |
4 |
D |
$14.06 |
$32,380 |
D/D |
(2,303) |
118,707 |
|
- |
|
Mammen Mathai |
SVP, Research & Early Clin Dev |
|
2009-05-20 |
4 |
D |
$14.06 |
$15,058 |
D/D |
(1,071) |
103,815 |
|
- |
|
Blum Leonard M |
Sr VP, Chief Comm. Officer |
|
2009-05-20 |
4 |
D |
$14.06 |
$15,269 |
D/D |
(1,086) |
124,449 |
|
- |
|
Shafer Bradford J |
Sr VP, Gen. Counsel, Secretary |
|
2009-05-20 |
4 |
D |
$14.06 |
$13,301 |
D/D |
(946) |
228,744 |
|
- |
|
Vagelos P Roy |
Director |
|
2009-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
245,397 |
|
- |
|
Young William D |
Director |
|
2009-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
12,000 |
|
- |
|
Whitesides George M |
Director |
|
2009-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
549,419 |
|
- |
|
Waltrip William H |
Director |
|
2009-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
12,000 |
|
- |
|
Levine Arnold J |
Director |
|
2009-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
75,967 |
|
- |
|
Malkiel Burton G |
Director |
|
2009-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
12,000 |
|
- |
|
Gunderson Robert V Jr |
Director |
|
2009-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
59,396 |
|
- |
|
711 Records found
|
|
Page 24 of 29 |
|
|